Precision Business Insights
Portfolio

 

Research Reports

Uveal Melanoma Therapeutics Market: Global Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024

Global Uveal Melanoma Therapeutics Market

 

By Disease Type (Choroidal Melanomas, Iris Melanomas, and Ciliary Body Melanomas), By Treatment Type (Chemotherapy, Immunotherapy, and Targeted Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024

 

Global uveal melanoma therapeutics market was valued at US$ XX Mn in 2017 and expected to grow at XX% Compound Annual Growth Rate (CAGR) from 2018 to 2024

 

Market Outline: Uveal Melanoma Therapeutics Market

Uveal melanoma is a disease in which malignant (cancer) cells form in the tissues of the eye. The tumors arise from the melanocytes that reside within the uvea giving color to the eye. Uveal melanoma begins between the three layers of the wall of the eye. The first layer (outer layer) includes sclera and the cornea at the front of the eye. The inner layer has a retina, that senses light and send images. The middle layer is the layer in which the melanoma forms. This layer is called as uvea.

Increase in the prevalence of uveal melanoma is driving the growth of the market. The rising awareness among the people regarding the disease among healthcare fraternity is anticipated to drive the growth of the uveal melanoma therapeutics market. However, the higher cost of the therapy and reimbursement policies are may constrain the growth of the market.

 

Market Scope: Uveal Melanoma Therapeutics Market

Uveal melanoma therapeutics market is segmented based on the disease type, treatment type, and distribution channel.

Based on the disease type, the market is segmented into the following:

  • Choroidal Melanomas
    • o Small Melanomas
    • o Medium-sized Melanomas
    • o Large Melanomas
  • Iris melanomas
  • Ciliary Body Melanomas

Based on the treatment type, the market is segmented into the following:

  • Chemotherapy
    • o Methotrexate
    • o Others
  • Immunotherapy Drugs
    • o Pembrolizumab
    • o Ipilimumab
    • o Others
  • Targeted Drugs

Based on the distribution channel, the market is segmented into the following:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

 

Regional Analysis:  Uveal Melanoma Therapeutics Market

Geographically, global uveal melanoma therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America uveal melanoma therapeutics market is driven by increase in the prevalence of the eye related disorders. The growing patient population with uveal melanoma disorder expected fuel the market growth in the region. According to the American Cancer Society, about nine of 10 melanomas of the eye develop in the choroid. It also states that 2,730 new cases were detected in 2014 of uveal melanoma in the U.S.

 

Competition Assessment: Uveal Melanoma Therapeutics Market

Some of the players in the global uveal melanoma therapeutics market include:

  • Eli Lilly & Co. (U.S)
  • Novartis AG (Switzerland)
  • AstraZeneca plc (UK)
  • Pfizer, Inc. (U.S)
  • Merck (U.S)
  • Roche (Switzerland)
  • Amgen (U.S)
  • Bayer (Germany)
  • Spectrum Pharmaceuticals, Inc. (U.S)

 

Notable Market Developments: Uveal Melanoma Therapeutics Market

  • Bristol-Myers Squibb and National Cancer Institute (NCI) completed the phase II  study of Nivolumab in combination with Ipilimumab for Uveal Melanoma

 

Key Features of the Report:

  • The report covers exhaustive regional information, that includes North America (The USA and Canada), Europe (Germany, France, Italy, UK, Spain, Russia, Poland and Rest of Europe), Asia-Pacific (Japan, China, India, Australia & New Zealand, ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others), South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentina, Venezuela, and Rest of Latin America), and Middle East and Africa (Gulf Cooperation Council (GCC) Countries, Israel, South Africa, and Rest of Middle East and Africa)
  • The report provides granular level information about the market size, regional market share, historic market (2013-2017) and forecast (2018-2024)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework and reimbursement scenari0
  • Eli Lilly & Co. (U.S)
  • Novartis AG (Switzerland)
  • AstraZeneca plc (UK)
  • Pfizer, Inc. (U.S)
  • Merck (U.S)
  • Roche (Switzerland)
  • Amgen (U.S)
  • Bayer (Germany)
  • Spectrum Pharmaceuticals, Inc. (U.S)

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

Contact SalesTOLL FREE: +1-866-598-1553